These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20076962)

  • 1. Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society.
    Oelke M; Gravas S
    World J Urol; 2010 Feb; 28(1):1-2. PubMed ID: 20076962
    [No Abstract]   [Full Text] [Related]  

  • 2. A plea for higher-quality data for GreenLight laser technology in the context of surgical benign prostatic obstruction trials: the GOLIATH study-fact or fiction in the era of evidence-based urology?
    Mamoulakis C
    Eur Urol; 2014 May; 65(5):943-5. PubMed ID: 24331150
    [No Abstract]   [Full Text] [Related]  

  • 3. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply from authors re: Charalampos Mamoulakis. A plea for higher-quality data for GreenLight laser technology in the context of surgical benign prostatic obstruction trials: the GOLIATH study-fact or fiction in the era of evidence-based urology? Eur Urol 2014;65:943-5.
    Bachmann A; Thomas JA
    Eur Urol; 2014 May; 65(5):945-6. PubMed ID: 24388437
    [No Abstract]   [Full Text] [Related]  

  • 5. Special Issue: Current practices in the management of benign prostatic hyperplasia. Introduction.
    Roehrborn CG; Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():1-2. PubMed ID: 19032602
    [No Abstract]   [Full Text] [Related]  

  • 6. Facilitating the medical management of benign prostatic hyperplasia in primary care.
    Rees J
    BJU Int; 2010 Jan; 105(1):131-2. PubMed ID: 20132105
    [No Abstract]   [Full Text] [Related]  

  • 7. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.
    Favilla V; Cimino S; Castelli T; Madonia M; Barbagallo I; Morgia G
    BJU Int; 2010 Dec; 106(11):1700-3. PubMed ID: 20575982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Wiser HJ; Köhler TS
    Curr Urol Rep; 2010 Jul; 11(4):228-35. PubMed ID: 20467845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia.
    Takada S; Kurita Y; Imanishi T; Otsuka A; Shinbo H; Furuse H; Nakanishi T; Suzuki A; Takase H; Ozono S
    Urology; 2011 Feb; 77(2):433-7. PubMed ID: 21168193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
    Novara G
    Eur Urol; 2008 Oct; 54(4):775-6. PubMed ID: 18571305
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
    Gratzke C; Reich O
    Eur Urol; 2008 Oct; 54(4):776-7. PubMed ID: 18571304
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Long-Term Treatment and Prognostic Factors of alpha1-Blockers for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Pilot Study Comparing Naftopidil and Tamsulosin Hydrochloride.
    Kaplan SA
    J Urol; 2011 Jan; 185(1):227. PubMed ID: 22082931
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
    Caremel R; Oger-Roussel S; Behr-Roussel D; Grise P; Giuliano F
    Prog Urol; 2010 Oct; 20(9):616-26. PubMed ID: 20951929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etiology, epidemiology, and natural history of benign prostatic hyperplasia.
    Bushman W
    Urol Clin North Am; 2009 Nov; 36(4):403-15, v. PubMed ID: 19942041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Hellstrom WJG, et al.: Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and BPH treatment. (Urology 2009;74:15-21).
    Schmid HP; Böhlen D
    Urology; 2009 Dec; 74(6):1377; author reply 1377-8. PubMed ID: 19962542
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Chin PT; Bolton DM; Jack G; Rashid P; Thavaseelan J; Yu RJ; Roehrborn CG; Woo HH
    Urology; 2012 Jan; 79(1):5-11. PubMed ID: 22202539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():3-7. PubMed ID: 19032603
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence-based urology in practice: heterogeneity in a systematic review meta-analysis.
    Imamura M; Cook J; Maclennan S; N'dow J; Dahm P;
    BJU Int; 2010 Mar; 105(6):770-3. PubMed ID: 20067453
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Christian G. Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
    Gacci M; Carini M; Maggi M
    Eur Urol; 2009 Jan; 55(1):e25-6. PubMed ID: 18486304
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: 180-W XPS GreenLight Laser Vaporisation versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial-the GOLIATH Study.
    Kaplan SA
    J Urol; 2015 Aug; 194(2):480-1. PubMed ID: 26195398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.